To view this email as a web page, click here.

Weight-Loss Drugs Buoy Eli Lilly's Q4 Earnings and 2024 Outlook

Eli Lilly reported strong fourth-quarter earnings driven by demand for weight-loss drugs.
The pharmaceutical giant also said its sales could rise more than 20% in 2024.
Eli Lilly shares fell in intraday trading Tuesday but have more than doubled in value over the past year.

Weight-Loss Drugs Buoy Eli Lilly's Q4 Earnings and 2024 Outlook

Novartis to acquire German Biotech MorphoSys for $2.9B, Expanding Cancer Drug Pipeline

Novartis plans to purchase MorphoSys for $2.9 billion, allowing it to own pelabresib, which is a treatment being investigated for a rare type of bone marrow cancer.

Credit Card Debt Put More Pressure on Households in the Fourth Quarter

Persistent spending may have boosted the U.S. economy, but it is taking a toll on households as 9.7% of all credit card debt was delinquent at the end of the year.

FMC Stock Plunges as Weak Sales, Destocking Hit Earnings—Key Price Levels to Watch

FMC shares fell sharply after the chemical maker missed analysts' first quarter earnings guidance amid low sales volumes and destocking challenges. Here are key chart levels to watch.

30-Year Mortgage Rates Move Sharply Higher

Rates on 30-year mortgages moved up by almost a quarter of a percent on Monday following two previous days of modest increases. All but two other loan types also climbed—most of them climbing by double digits.

How can we improve Investopedia Daily? Tell us at daily@investopedia.com

Were you sent this by a friend? Click here to subscribe.

Instagram

TikTok

Youtube

You are receiving this newsletter because you subscribed to the Investopedia Daily newsletter. If you wish to unsubscribe, please click here.

Dotdash Meredith 225 Liberty St, 4th Floor, New York, NY 10281
©2024 All Rights Reserved. Privacy Policy | Terms of Service

Dotdash Meredith

Investopedia is part of the Dotdash Meredith publishing family.